# Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Source: https://onco.cc/trials/nct05609578/  
OnCo record `nct05609578` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Adagrasib, Pembrolizumab, Pemetrexed, Carboplatin and Cisplatin in non-small-cell lung cancer, run by Mirati Therapeutics Inc., active and no longer recruiting.

## Summary

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation is a phase 2 interventional study registered as NCT05609578 by Mirati Therapeutics Inc., with 90 participants enrolled, started 2022-11-22 and due to reach its primary completion in 2026-09-30. Interventions recorded: Adagrasib oral dose of 400 mg twice daily tablets, Pembrolizumab, Chemotherapy: Pemetrexed and Cisplatin/Carboplatin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05609578
- Phase: 2
- Setting: A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
- Sponsor: Mirati Therapeutics Inc.
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT05609578: https://clinicaltrials.gov/study/NCT05609578

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Adagrasib](https://onco.cc/drugs/adagrasib/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct05609578.json